

Supplemental Online Content

Lin CH, Chen PK, Wang SH, Lane HY. Effect of sodium benzoate on cognitive function among patients with behavioral and psychological symptoms of dementia: secondary analysis of a randomized clinical trial. *JAMA Netw Open*. 2021;4(4):e216156. doi:10.1001/jamanetworkopen.2021.6156

eTable. Measures of BEHAVE-AD Over the 6-week Treatment Using Generalized Estimating Equations (GEE) Method

eFigure. Participant Flow Diagram

This supplemental material has been provided by the authors to give readers additional information about their work.

eTable 1. Measures of BEHAVE-AD Over the 6-week Treatment Using Generalized Estimating Equations (GEE) Method

	Sodium benzoate Mean ± SD (n)	Placebo Mean ± SD (n)	Estimate*	S.E.	Z	P Value
Male						
Baseline	9.9 ± 7.7 (19)	12.1 ± 11.4 (16)				
Week 2	6.7 ± 5.4 (19)	9.9 ± 9.6 (16)	-2.2613	1.6116	-1.40	.16
Week 4	6.3 ± 4.1 (18)	6.9 ± 4.4 (13)	-3.0315	1.4326	-2.12	.03
Week 6	5.5 ± 4.0 (17)	5.2 ± 3.6 (12)	-4.4082	2.0246	-2.18	.03
Endpoint	5.9 ± 4.2 (19)	7.9 ± 9.0 (16)	-3.8801	1.9549	-1.98	.05
Drug			-1.7591	3.0768	-0.57	.57
Week 2 x drug			-1.0261	1.9078	-0.54	.59
Week 4 x drug			-0.2501	1.8403	-0.14	.89
Week 6 x drug			0.3176	2.4168	0.13	.90
Endpoint x drug			-0.1185	2.3385	-0.05	.96
Female						
Baseline	11.3 ± 8.2 (30)	10.8 ± 7.8 (32)				
Week 2	10.0 ± 8.8 (30)	9.5 ± 6.5 (31)	-1.4534	0.6349	-2.29	.02
Week 4	10.2 ± 8.2 (25)	6.9 ± 4.7 (28)	-3.5276	0.9680	-3.64	<.001
Week 6	8.1 ± 6.8 (24)	8.3 ± 6.8 (29)	-1.9142	0.9751	-1.96	.05
Endpoint	9.6 ± 8.9 (30)	8.9 ± 7.1 (32)	-1.8629	0.9149	-2.04	.04
Drug			0.4391	1.9596	0.22	.82
Week 2 x drug			0.0948	1.1502	0.08	.93
Week 4 x drug			3.0225	1.4650	2.06	.04
Week 6 x drug			0.1928	1.5394	0.13	.90
Endpoint x drug			0.2565	1.4637	0.18	.86

* Estimate is the coefficient of treatment-visit interaction term in the GEE method with treatment, visit and treatment-visit interaction as covariates; baseline value as the reference. No imputation for the incomplete data was used. An autoregressive AR(1) covariance matrix was fit to the within-patient repeated measures. P values were based on two-tailed tests.

In the “Estimate” column for BEHAVE-AD, the upper 4 rows are for the placebo group only, while the bottom 5 are for benzoate, placebo interaction terms.

Abbreviations: BEHAVE-AD, Behavioral Pathology in Alzheimer's Disease Rating Scale.

eFigure 1. Participant Flow Diagram

